Literature DB >> 15275362

Host age as a determinant of naturally acquired immunity to Plasmodium falciparum.

J K Baird1.   

Abstract

The usual course of infection by Plasmodium falciparum among adults who lack a history of exposure to endemic malaria is fulminant. The infection in adults living with hyper- to holoendemic malaria is chronic and benign. Naturally acquired immunity to falciparum malaria is the basis of this difference. Confusion surrounds an essential question regarding this process: What is its rate of onset? Opinions vary because of disagreement over the relationships between exposure to infection, antigenic polymorphism and naturally acquired immunity. In this review, Kevin Baird discusses these relationships against a backdrop of host age as a determinant of naturally acquired immunity to falciparum malaria.

Entities:  

Year:  1995        PMID： 15275362     DOI： 10.1016/0169-4758(95)80167-7

Source DB:  PubMed          Journal:  Parasitol Today        ISSN： 0169-4758


  90 in total

1.  The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria.

Authors:  Morris O Makobongo; George Riding; Huji Xu; Chakrit Hirunpetcharat; Dianne Keough; John de Jersey; Peter Willadsen; Michael F Good
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

2.  A malaria serological map indicating the intersection between parasite antigenic diversity and host antibody repertoires.

Authors:  H A Giha; A A Nasr; N C Iriemenam; K Berzins; M Troye-Blomberg; D E Arnot; G Elghazali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-29       Impact factor: 3.267

3.  Predictors of local malaria outbreaks: an approach to the development of an early warning system in Colombia.

Authors:  Julio César Mateus; Gabriel Carrasquilla
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

4.  Tumor necrosis factor alpha p55 receptor is important for development of memory responses to blood-stage malaria infection.

Authors:  C Li; J Langhorne
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 5.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

Review 6.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 7.  Natural regulatory T cells in malaria: host or parasite allies?

Authors:  Diana S Hansen; Louis Schofield
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

8.  Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria.

Authors:  Hayder A Giha; Amre Nasr; Nnaemeka C Iriemenam; David Arnot; Marita Troye-Blomberg; Thor G Theander; Klavs Berzins; Gehad ElGhazali; Janardan P Pandey
Journal:  Malar J       Date:  2009-12-22       Impact factor: 2.979

9.  The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.

Authors:  Teun Bousema; Will Roeffen; Hinta Meijerink; Harry Mwerinde; Steve Mwakalinga; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Frank Mosha; Geoffrey Targett; Eleanor M Riley; Robert Sauerwein; Chris Drakeley
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits.

Authors:  Kwadwo A Kusi; Bart W Faber; Marjolein van der Eijk; Alan W Thomas; Clemens H M Kocken; Edmond J Remarque
Journal:  Malar J       Date:  2011-02-14       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.